Eileen Koutnik-Fotopoulos
Published Online: Saturday, October 1, 2005

FDA Commissioner Lester Crawford, DVM, PhD, has resigned after less than 3 months on the job. Andrew von Eschenbach, MD, has been named acting FDA commissioner. In an e-mail to his staff, Dr. Crawford did not cite any specific reason for his departure except that it was time "to step aside." His resignation comes at a time marked by heavy criticism of the agency. His recent decision to delay Barr Laboratories' application to give emergency contraception OTC status, for example, came under heavy criticism. The FDA also stirred controversies in its slow response to recognize the safety concerns of painkillers like Merck's Vioxx, which was taken off the market in 2004; the shutdown of a British supplier of the US flu vaccine for tainted shots; and the recalls of malfunctioning heart devices.

Eileen Koutnik-Fotopoulos: Staff Writer, Pharmacy Times

Latest Articles
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Latest Issues